In this section
Note: This guideline is currently under review.
Subcutaneous medication administration is a common route of administration of medications in both the hospital and community settings. Subcutaneous infusion of medications can be used in a variety of scenarios; one such situation is in palliative care, to optimise the delivery of medications to provide appropriate symptom management. It is often used in patients who are unable to take medication by mouth, those that have poor gut absorption, nausea and vomiting or those that require a continuous infusion in the community. Indwelling subcutaneous catheter devices may assist in medication delivery and decrease trauma, distress and discomfort for the patient.
An Insuflon™ is an indwelling subcutaneous catheter used for administration of medication subcutaneously. Medications commonly administered via an Insuflon™ include Granulocyte Colony Stimulating Factor (GCSF), Cytabarine (Ara-CTM), Enoxaparin (ClexaneTM), Insulin and Morphine.
This catheter system requires a needle and syringe to administer the medication through the device.
A BD Saf-T-Intima™ is a needleless closed indwelling subcutaneous catheter system, which is used for subcutaneous administration of medications, either as a continuous infusion or for breakthrough/bolus doses. Medications commonly administered via a BD Saf-T-Intima™ can include opoids, benzodiazepines and anti-emetics.
This device can be attached to a syringe driver for continuous infusions of prescribed medications either on an Alaris Asena GH MK III (inpatient use) or a NikiT 34 (for either inpatient or outpatient use).
The BD Saf-T-Intima™ is a device that may at times also be used as an intravenous catheter system in some hospital and community settings.
The aim of this guideline is to provide nursing and medical staff with an overview of the use and management of Indwelling Subcutaneous Catheter devices utilised at the Royal Children’s Hospital, Melbourne.
A physical assessment of the patient is required to select an insertion site
The following information should be in Progress Notes;
Palliative Care Resources
Insuflon™ product information
BD Saf-T-Intima™ product information
Paediatric Pharmacopeia 13th Edition Online
AMH Children’s Dosing Companion
Complete evidence table document available at
Click here to view the
Complete document control document available at
Please remember to read the
The development of this nursing guideline was coordinated by Jacquie Barton, Liaison Nurse, Victorian Paediatric Palliative Care Program and Lisa Barrow, CNC, Kookaburra ward, and approved by the Nursing Clinical Effectiveness Committee. Updated May 2014.